Straits Times Index
3,272.72 +47.55 (+1.47%) S&P 500
5,010.60 +43.37 (+0.87%) Dow
38,239.98 +253.58 (+0.67%) Nasdaq
15,451.31 +169.30 (+1.11%) Bitcoin USD
66,136.11 +60.22 (+0.09%) CMC Crypto 200
1,422.18 +7.42 (+0.52%)
Takeda Pharmaceutical Company Limited (TKPHF)
| Previous close | 25.77 |
| Open | 26.53 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 25.77 - 25.77 |
| 52-week range | 25.77 - 34.47 |
| Volume | |
| Avg. volume | 10,025 |
| Market cap | 41.876B |
| Beta (5Y monthly) | 0.54 |
| PE ratio (TTM) | 35.30 |
| EPS (TTM) | 0.73 |
| Earnings date | N/A |
| Forward dividend & yield | 1.24 (4.82%) |
| Ex-dividend date | 28 Mar 2024 |
| 1y target est | N/A |
PR NewswireTakeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK, President and CEO; Christophe Weber, "Takeda"), Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), and Sumitomo Mitsui Banking Corporation (President & CEO: Akihiro Fukutome, "SMBC") today announced that the three companies signed a master agreement on April 22, 2024, to establish a joint venture company. The new company will be dedicated to the incubation*1 of early drug discovery programs, primarily origin
Barrons.comMasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors
Coliseum Capital increased its stake in boat maker MasterCraft. Insight Venture Partners sold shares of cybersecurity firm SentinelOne.
Business WireU.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
OSAKA, Japan & CAMBRIDGE, Mass., April 18, 2024--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn’s disease (CD) after induction therapy with intravenous (IV) ENTYVIO.1 The subcutaneous administration of ENTYVIO was also approved by FDA in September 2023 for the maintenance treatment of adults with moderately to
